Literature DB >> 7559238

Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates.

S G White1, E C Fletcher, C C Miller.   

Abstract

Phasic blood pressure (BP) response during obstructive apnea (OA) in human sleep has been previously described as consisting of a slow incremental increase in BP to the point of apnea termination followed by a rapid rise and then fall in BP at the resumption of respiration. This rise in BP has been attributed to postapneic augmentation of cardiac output resulting after release of the marked negative intrathoracic pressure (NIP) of obstructed inspiration. Via an endotracheal tube, we created obstructed and nonobstructed breath hold (apnea) in chloralose-anesthesized baboons consisting of fixed-duration (30, 45, and 60 s) single OAs (mechanical obstruction) and nonobstructive (paralysis, ventilator cessation) apneas of matched duration and arterial desaturation. Systemic BP was measured before apnea (T0), during the last 5 s of apnea (T1), and during the first 5 s after resumption of respiration (T2). Despite wide fluctuations in NIP and BP during the T0 to T1 phase of OA, BP elevation in OA and nonobstructive apnea at T0, T1, or T2 did not differ for any duration apnea. At the release of obstruction, when resolution of NIP changes could theoretically increase cardiac output and accentuate BP, there was no difference in T1 and T2 pressures between the two conditions. We conclude that in this anesthesized animal model, mechanical (NIP) changes do not play a major role in overall maximum BP response to OA. Because of physiological differences between natural sleep in humans and the anesthetized state in animals, care must be taken in extrapolating these results to human sleep apnea.

Entities:  

Mesh:

Year:  1995        PMID: 7559238     DOI: 10.1152/jappl.1995.79.1.324

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  12 in total

Review 1.  Sleep Apnea Research in Animals. Past, Present, and Future.

Authors:  Swati Chopra; Vsevolod Y Polotsky; Jonathan C Jun
Journal:  Am J Respir Cell Mol Biol       Date:  2016-03       Impact factor: 6.914

Review 2.  Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential.

Authors:  Robert T Mallet; Eugenia B Manukhina; Steven Shea Ruelas; James L Caffrey; H Fred Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-13       Impact factor: 4.733

Review 3.  Therapeutic potential of intermittent hypoxia: a matter of dose.

Authors:  Angela Navarrete-Opazo; Gordon S Mitchell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-17       Impact factor: 3.619

Review 4.  Cardiovascular consequences of sleep apnea.

Authors:  Saeid Golbidi; Mohammad Badran; Najib Ayas; Ismail Laher
Journal:  Lung       Date:  2011-11-03       Impact factor: 2.584

Review 5.  Mechanisms of sleep-disordered breathing: causes and consequences.

Authors:  Richard S T Leung; Vikram R Comondore; Clodagh M Ryan; Daniel Stevens
Journal:  Pflugers Arch       Date:  2011-11-15       Impact factor: 3.657

Review 6.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

Review 7.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 8.  Molecular signatures of obstructive sleep apnea in adults: a review and perspective.

Authors:  Erna S Arnardottir; Miroslaw Mackiewicz; Thorarinn Gislason; Karen L Teff; Allan I Pack
Journal:  Sleep       Date:  2009-04       Impact factor: 5.849

9.  Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders.

Authors:  Ayodeji Adegunsoye; Siva Ramachandran
Journal:  Pulm Med       Date:  2012-07-11

Review 10.  Cardiovascular complications of sleep apnea: role of oxidative stress.

Authors:  Mohammad Badran; Najib Ayas; Ismail Laher
Journal:  Oxid Med Cell Longev       Date:  2014-03-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.